PURPOSE: Calorie restriction (CR) is an effective treatment for obesity-related liver and metabolic disease. However, CR studies in individuals without obesity are needed to see if CR could delay disease onset. Liver biomarkers indicate hepatic health and are linked to cardiometabolic disease. Our aim was to examine the effects of a 2-year CR intervention on liver biomarkers in healthy individuals without obesity. METHODS: The Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) study was a 2-year randomized controlled trial. Overall, 218 participants (body mass index: 25.1 ± 1.7 kg/m2) were enrolled into a control group (n = 75) that ate ad libitum (AL), or a CR group (n = 143) that aimed to decrease energy intake by 25%. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and bilirubin were measured during the trial. RESULTS: At month 24, relative to the AL group, ALP (- 7 ± 1 IU/L; P < 0.01) and GGT (- 0.11 ± 0.04 log IU/L; P = 0.02) decreased and bilirubin increased (0.21 ± 0.06 log mg/dL; P < 0.01) in the CR group; no between-group differences in ALT (- 1 ± 1 IU/L; P > 0.99) or AST (2 ± 2 IU/L; P = 0.68) were revealed. However, sex-by-treatment-by-time interactions (P < 0.01) were observed, with CR (vs. control) inducing reduced ALT and GGT and increased AST in men only (P ≤ 0.02). CONCLUSIONS: In metabolically healthy individuals without obesity, 2 years of CR improves several liver biomarkers, with potentially greater improvements in men. These data suggest that sustained CR may improve long-term liver and metabolic disease risk in healthy adults. TRIAL REGISTRATION: Clinicaltrials.gov (NCT00427193). Registered January 2007.
PURPOSE: Calorie restriction (CR) is an effective treatment for obesity-related liver and metabolic disease. However, CR studies in individuals without obesity are needed to see if CR could delay disease onset. Liver biomarkers indicate hepatic health and are linked to cardiometabolic disease. Our aim was to examine the effects of a 2-year CR intervention on liver biomarkers in healthy individuals without obesity. METHODS: The Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) study was a 2-year randomized controlled trial. Overall, 218 participants (body mass index: 25.1 ± 1.7 kg/m2) were enrolled into a control group (n = 75) that ate ad libitum (AL), or a CR group (n = 143) that aimed to decrease energy intake by 25%. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and bilirubin were measured during the trial. RESULTS: At month 24, relative to the AL group, ALP (- 7 ± 1 IU/L; P < 0.01) and GGT (- 0.11 ± 0.04 log IU/L; P = 0.02) decreased and bilirubin increased (0.21 ± 0.06 log mg/dL; P < 0.01) in the CR group; no between-group differences in ALT (- 1 ± 1 IU/L; P > 0.99) or AST (2 ± 2 IU/L; P = 0.68) were revealed. However, sex-by-treatment-by-time interactions (P < 0.01) were observed, with CR (vs. control) inducing reduced ALT and GGT and increased AST in men only (P ≤ 0.02). CONCLUSIONS: In metabolically healthy individuals without obesity, 2 years of CR improves several liver biomarkers, with potentially greater improvements in men. These data suggest that sustained CR may improve long-term liver and metabolic disease risk in healthy adults. TRIAL REGISTRATION: Clinicaltrials.gov (NCT00427193). Registered January 2007.
Entities:
Keywords:
Aging; Bilirubin; Cardiometabolic health; Energy restriction; Liver enzymes
Authors: N V Dhurandhar; D Schoeller; A W Brown; S B Heymsfield; D Thomas; T I A Sørensen; J R Speakman; M Jeansonne; D B Allison Journal: Int J Obes (Lond) Date: 2014-11-13 Impact factor: 5.095
Authors: Naoki Kumashiro; Derek M Erion; Dongyan Zhang; Mario Kahn; Sara A Beddow; Xin Chu; Christopher D Still; Glenn S Gerhard; Xianlin Han; James Dziura; Kitt Falk Petersen; Varman T Samuel; Gerald I Shulman Journal: Proc Natl Acad Sci U S A Date: 2011-09-19 Impact factor: 11.205
Authors: Saverio Stranges; Joan M Dorn; Paola Muti; Jo L Freudenheim; Eduardo Farinaro; Marcia Russell; Thomas H Nochajski; Maurizio Trevisan Journal: Hepatology Date: 2004-03 Impact factor: 17.425
Authors: Susan B Racette; Sai Krupa Das; Manjushri Bhapkar; Evan C Hadley; Susan B Roberts; Eric Ravussin; Carl Pieper; James P DeLany; William E Kraus; James Rochon; Leanne M Redman Journal: Am J Physiol Endocrinol Metab Date: 2011-11-29 Impact factor: 4.310
Authors: Eric Ravussin; Leanne M Redman; James Rochon; Sai Krupa Das; Luigi Fontana; William E Kraus; Sergei Romashkan; Donald A Williamson; Simin N Meydani; Dennis T Villareal; Steven R Smith; Richard I Stein; Tammy M Scott; Tiffany M Stewart; Edward Saltzman; Samuel Klein; Manju Bhapkar; Corby K Martin; Cheryl H Gilhooly; John O Holloszy; Evan C Hadley; Susan B Roberts Journal: J Gerontol A Biol Sci Med Sci Date: 2015-07-17 Impact factor: 6.053
Authors: Theodora W Elffers; Renée de Mutsert; Hildo J Lamb; Albert de Roos; Ko Willems van Dijk; Frits R Rosendaal; J Wouter Jukema; Stella Trompet Journal: PLoS One Date: 2017-09-28 Impact factor: 3.240